Patents Assigned to UNICYTE EV AG
-
Publication number: 20230142123Abstract: To provide biotechnological filtration possibilities with which the danger of contamination is low and at the same time an optimum flow profile can be achieved, the use of a filter module 100 is proposed, the latter having, in a filter housing 110, a filter, with a bundle of hollow fibres 114, and a centrifugal pump rotor 132, for a biotechnological production method, and a filter module 100 for the filtration of a biotechnological liquid L, having a filter housing 110, a filter arranged in the filter housing 110 with a bundle of hollow fibres 114, a centrifugal pump rotor 132 arranged in the filter housing 110 such that it is fluidically connected to the interior of the hollow fibres 114, wherein the centrifugal pump rotor 132 is able to be magnetically driven such that it can force a liquid L through the hollow fibres 114, a first port 102 for the supply of a biotechnological liquid L to be filtered, which first port 102 is fluidically connected to the interior of the hollow fibres 114 of the filter, a secoType: ApplicationFiled: November 5, 2020Publication date: May 11, 2023Applicants: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH, UNICYTE EV AGInventors: Alexander HEIDE, Dejan NIKOLIC
-
Publication number: 20230037275Abstract: There is disclosed a preparation of extracellular vesicles derived from human liver stem cells, preferably from a non-oval human progenitor cell line that expresses hepatic cell markers, which is capable of reducing the senescence of a population of senescent cells, as measured in a SA-?-galactosidase-based cellular senescence assay. Also disclosed are therapeutic applications of the preparation of extracellular vesicles derived from human liver stem cells according to the invention. Therapeutic applications include the reduction of cellular senescence, e.g. in an vitro or ex vivo method, as well as the therapeutic treatment of diseases and conditions known to be related to ageing and cellular senescence, such as for example atherosclerosis, diabetes mellitus type 2, asthenia, and others.Type: ApplicationFiled: June 9, 2020Publication date: February 2, 2023Applicant: UNICYTE EV AGInventors: Paul ROBBINS, Giovanni CAMUSSI, Maria Beatriz HERRERA SANCHEZ
-
Publication number: 20220409659Abstract: The present invention relates to compositions of extracellular vesicles (EVs) which are characterized by a strong proangiogenic activity and are effective in the therapeutic treatment of ischemic diseases and ischemic injuries or in wound healing. The extracellular vesicles (EVs) suitable for use in the compositions of the invention are either derived from a blood component or are selected by means of a potency test for pro-angiogenesis. Also disclosed is a method of manufacturing a pharmaceutical preparation of extracellular vesicles (EVs) characterized by a strong proangiogenic activity.Type: ApplicationFiled: September 1, 2022Publication date: December 29, 2022Applicant: UNICYTE EV AGInventors: Maria Felice BRIZZI, Giovanni Camussi, Andrea Ranghino
-
Patent number: 11484816Abstract: The invention relates to compositions and methods for isolating extracellular vesicles (EVs) from a biological fluid sample. The compositions and methods of the invention are based on the combination of a polycation with an extracellular matrix forming polymer. Extracellular vesicles (EVs) are isolated from biological fluids such as blood, serum, plasma, saliva, urine or cerebrospinal fluid, or from the conditioned medium of a cell culture, such as an adult stem cell culture. The use of the isolation methods and compositions of the invention results in a higher EVs recovery, enrichment in exosomes, simplicity, cost-effectiveness, and in the isolation of EVs that retain their biological activities in vitro.Type: GrantFiled: April 11, 2017Date of Patent: November 1, 2022Assignee: UNICYTE EV AGInventors: Maria Chiara Deregibus, Federico Figliolini, Ciro Tetta, Giovanni Camussi
-
Patent number: 11395832Abstract: A method for treating renal cancer by administering a pharmaceutically acceptable carrier comprising a microRNA selected from the group consisting of miR-15a, miR-181b, miR-320c, miR-874 and any combination thereof is provided. In an embodiment, the pharmaceutically acceptable carrier is an extracellular vesicle (EV) derived from an adult stem cell selected from the group consisting of a mesenchymal stem cell (MSC), a non-oval human liver progenitor cell (HLSC) and an adipose stem cell (ASC).Type: GrantFiled: December 14, 2018Date of Patent: July 26, 2022Assignee: UNICYTE EV AGInventors: Giovanni Camussi, Benedetta Bussolati, Tatiana Lopatina
-
Publication number: 20220151925Abstract: The present invention relates to an in vitro method for predicting the proangiogenic activity of preparations of extracellular vesicles (EVs), preferably blood-derived EVs, wherein the method is based on the combined determination of the content of transforming growth factor beta (TGF?) and microRNA-130a. Also disclosed is a method of manufacturing a preparation of extracellular vesicles (EVs) predicted to have strong proangiogenic activity and the EVs preparations thereof, which are effective for the therapeutic treatment of ischemic diseases, ischemic injuries and pathological conditions associated with risk of cardiovascular disease, or for use in wound healing.Type: ApplicationFiled: March 13, 2020Publication date: May 19, 2022Applicant: UNICYTE EV AGInventors: Maria Felice BRIZZI, Giovanni CAMUSSI, Claudia CAVALLARI
-
Patent number: 11110130Abstract: The invention relates to a new therapeutic application of pharmaceutically acceptable carriers containing miR222. In particular, the invention relates to the use of extracellular vesicles (EVs) which contain the microRNA miR222, in the treatment of fibrotic disease caused by hyperglycaemia, such as diabetic nephropathy and/or renal fibrosis.Type: GrantFiled: February 12, 2020Date of Patent: September 7, 2021Assignee: UNICYTE EV AGInventors: Maria Felice Brizzi, Giovanni Camussi
-
Publication number: 20210238552Abstract: Active loading of extracellular vesicles (EVs) with an exogenous molecule without damaging the extracellular vesicles is provided. A composition comprising a population of extracellular vesicles loaded with an exogenous molecule, which have maintained their integrity, original endogenous cargo and functionality, compared to unloaded controls is also provided. Extracellular vesicles are derived from a stem cell, preferably an adult stem cell, or from a biological fluid, a conditioned cell medium or a tissue culture medium.Type: ApplicationFiled: August 5, 2019Publication date: August 5, 2021Applicant: UNICYTE EV AGInventors: Giovanni CAMUSSI, Margherita Alba Carlotta POMATTO
-
Publication number: 20210069231Abstract: A method for treating renal cancer by administering a pharmaceutically acceptable carrier comprising a microRNA selected from the group consisting of miR-15a, miR-181b, miR-320c, miR-874 and any combination thereof is provided. In an embodiment, the pharmaceutically acceptable carrier is an extracellular vesicle (EV) derived from an adult stem cell selected from the group consisting of a mesenchymal stem cell (MSC), a non-oval human liver progenitor cell (HLSC) and an adipose stem cell (ASC).Type: ApplicationFiled: December 14, 2018Publication date: March 11, 2021Applicant: UNICYTE EV AGInventors: Giovanni CAMUSSI, Benedetta BUSSOLATI, Tatiana LOPATINA
-
Patent number: 10716813Abstract: The invention relates to a new therapeutic application of pharmaceutically acceptable carriers containing miR222. In particular, the invention relates to the use of extracellular vesicles (EVs) which contain the microRNA miR222, in the treatment of fibrotic disease caused by hyperglycaemia, such as diabetic nephropathy and/or renal fibrosis.Type: GrantFiled: May 4, 2017Date of Patent: July 21, 2020Assignee: UNICYTE EV AGInventors: Maria Felice Brizzi, Giovanni Camussi
-
Publication number: 20200222467Abstract: The invention relates to a new therapeutic application of pharmaceutically acceptable carriers containing miR222. In particular, the invention relates to the use of extracellular vesicles (EVs) which contain the microRNA miR222, in the treatment of fibrotic disease caused by hyperglycaemia, such as diabetic nephropathy and/or renal fibrosis.Type: ApplicationFiled: February 12, 2020Publication date: July 16, 2020Applicant: UNICYTE EV AGInventors: Maria Felice BRIZZI, Giovanni CAMUSSI
-
Publication number: 20200182865Abstract: The invention relates to a method and a kit for capturing on a solid surface the extracellular vesicles (EVs) which are present in a biological fluid sample. The solid surface is coated with a polycationic substance, preferably a protamine salt such as protamine hydrochloride. The method and kit of the invention is useful for the detection and/or quantification of the extracellular vesicles (EVs) which are present in a biological fluid sample, particularly in a diagnostic context.Type: ApplicationFiled: May 17, 2017Publication date: June 11, 2020Applicant: UNICYTE EV AGInventors: Maria Chiara DEREGIBUS, Benedetta BUSSOLATI, Givanni CAMUSSI, Veronica DIMUCCIO
-
Publication number: 20200179827Abstract: The invention relates to compositions and methods for isolating extracellular vesicles (EVs) from a biological fluid sample. The compositions and methods of the invention are based on the combination of a polycation with an extracellular matrix forming polymer. Extracellular vesicles (EVs) are isolated from biological fluids such as blood, serum, plasma, saliva, urine or cerebrospinal fluid, or from the conditioned medium of a cell culture, such as an adult stem cell culture. The use of the isolation methods and compositions of the invention results in a higher EVs recovery, enrichment in exosomes, simplicity, cost-effectiveness, and in the isolation of EVs that retain their biological activities in vitro.Type: ApplicationFiled: April 11, 2017Publication date: June 11, 2020Applicant: UNICYTE EV AGInventors: Maria Chiara DEREGIBUS, Federico FIGLIOLINI, Ciro TETTA, Giovanni CAMUSSI
-
Publication number: 20190381095Abstract: The present invention relates to compositions of extracellular vesicles (EVs) which are characterized by a strong proangiogenic activity and are effective in the therapeutic treatment of ischemic diseases and ischemic injuries or in wound healing. The extracellular vesicles (EVs) suitable for use in the compositions of the invention are either derived from a blood component or are selected by means of a potency test for pro-angiogenesis. Also disclosed is a method of manufacturing a pharmaceutical preparation of extracellular vesicles (EVs) characterized by a strong proangiogenic activity.Type: ApplicationFiled: October 11, 2017Publication date: December 19, 2019Applicant: UNICYTE EV AGInventors: Maria Felice BRIZZI, Giovanni CAMUSSI, Andrea RANGHINO
-
Publication number: 20190209619Abstract: The invention relates to a new therapeutic application of pharmaceutically acceptable carriers containing miR222. In particular, the invention relates to the use of extracellular vesicles (EVs) which contain the microRNA miR222, in the treatment of fibrotic disease caused by hyperglycaemia, such as diabetic nephropathy and/or renal fibrosis.Type: ApplicationFiled: May 4, 2017Publication date: July 11, 2019Applicant: UNICYTE EV AGInventors: Maria Felice BRIZZI, Giovanni CAMUSSI